Actinogen Advances Xanamem Development with FDA Meeting Success

An update from Actinogen Medical Limited ( (AU:ACW) ) is now available.

Actinogen Medical announced the successful completion of a Type C meeting with the FDA regarding its major depressive disorder (MDD) program, reaching a consensus on the necessary clinical and nonclinical studies for future marketing approval of Xanamem. This development is a significant milestone for the company, enhancing its position in discussions with potential partners and supporting its ongoing efforts in clinical trials for Alzheimer’s and depression.

More about Actinogen Medical Limited

Actinogen Medical Limited is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with potential future applications in Fragile X Syndrome and other conditions. The company is conducting clinical trials in Australia and the US to assess Xanamem’s efficacy in slowing Alzheimer’s progression and alleviating depression symptoms.

YTD Price Performance: 25.00%

Average Trading Volume: 75,000

Technical Sentiment Signal: Sell

Current Market Cap: $68M

For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.